Quest Diagnostics (DGX) Gains from Investment Securities (2009 - 2026)

Quest Diagnostics (DGX) has 18 years of Gains from Investment Securities data on file, last reported at $37.0 million in Q1 2026.

• Quarterly Gains from Investment Securities rose 3600.0% year-over-year to $37.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $81.0 million (up 3950.0% YoY) and the FY2025 annual result came in at $45.0 million, up 87.5% from the prior year.
• Gains from Investment Securities rose to $37.0 million in Q1 2026 per DGX's latest filing, from $25.0 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $55.0 million in Q3 2024, with the low at -$60.0 million in Q2 2022.
• Average Gains from Investment Securities over 5 years is $4.5 million, with a median of $3.0 million recorded in 2023.
• Year-over-year, Gains from Investment Securities slumped 1900.0% in 2024 and jumped 3600.0% in 2026.
• Quest Diagnostics' Gains from Investment Securities stood at -$29.0 million in 2022, then soared by 196.55% to $28.0 million in 2023, then soared by 96.43% to $55.0 million in 2024, then tumbled by 54.55% to $25.0 million in 2025, then soared by 48.0% to $37.0 million in 2026.
• Business Quant data shows DGX's Gains from Investment Securities at $37.0 million in Q1 2026, $25.0 million in Q4 2025, and -$22.0 million in Q3 2025.